CENTESSA PHARMACEUTICALS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.89 USD | 0.00% |
|
+4.40% | +11.68% |
| 21/06 | Morgan Stanley Adjusts Price Target on Centessa Pharmaceuticals to $11 From $8, Maintains Equalweight Rating | MT |
| 10/06 | Centessa Pharmaceuticals Appoints John Crowley as CFO | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1,012 | 293.2 | 777.1 | 1,005 | - | - |
| Enterprise Value (EV) 1 | 492.9 | -30.6 | 596.3 | 797.4 | 836.1 | 836.3 |
| P/E ratio | - | -1.34 x | -5.07 x | -5.46 x | -5.57 x | -6.61 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | 113 x | - | - | 27.6 x |
| EV / Revenue | - | - | 87 x | - | - | 23 x |
| EV / EBITDA | -1.32 x | 0.14 x | -3.5 x | -5.43 x | -4.81 x | -4.71 x |
| EV / FCF | - | - | -3.71 x | -4.9 x | -5.1 x | -4.93 x |
| FCF Yield | - | - | -26.9% | -20.4% | -19.6% | -20.3% |
| Price to Book | 2.06 x | 0.87 x | 3.33 x | 4.75 x | 6.44 x | 8.31 x |
| Nbr of stocks (in thousands) | 89,901 | 94,596 | 97,629 | 1,13,044 | - | - |
| Reference price 2 | 11.26 | 3.100 | 7.960 | 8.890 | 8.890 | 8.890 |
| Announcement Date | 30/03/22 | 30/03/23 | 28/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 6.853 | - | - | 36.38 |
| EBITDA 1 | - | -374 | -212.1 | -170.5 | -146.8 | -173.8 | -177.6 |
| EBIT 1 | - | -374.1 | -212.3 | -171.3 | -163.2 | -187.1 | -193.6 |
| Operating Margin | - | - | - | -2,499.39% | - | - | -532.23% |
| Earnings before Tax (EBT) 1 | - | - | - | -176.1 | -190.6 | -217.7 | -220.1 |
| Net income 1 | -3.149 | - | -216.2 | -151.1 | -186.2 | -201.7 | -197.9 |
| Net margin | - | - | - | -2,204.65% | - | - | -544.12% |
| EPS 2 | -0.4000 | - | -2.310 | -1.570 | -1.628 | -1.595 | -1.345 |
| Free Cash Flow 1 | - | - | - | -160.5 | -162.7 | -163.8 | -169.8 |
| FCF margin | - | - | - | -2,342.2% | - | - | -466.78% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 21/04/21 | 30/03/22 | 30/03/23 | 28/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | 6.853 | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -58.29 | -53.22 | -68.41 | -49.03 | -41.6 | -48.88 | -47.02 | -40.21 | -35.18 | -36.09 | -40.93 | -43.23 | -56.93 | -45 |
| Operating Margin | - | - | - | - | - | - | - | - | -513.32% | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | - | - | - | - | - | -48.94 | -41.47 | -35.69 | -37.56 | -47 | -51 | -55 | - |
| Net income 1 | - | - | - | - | -43.17 | -50.71 | -24.89 | -38.65 | -36.84 | -38.05 | -42.5 | -45.23 | -60.1 | - |
| Net margin | - | - | - | - | - | - | - | - | -537.53% | - | - | - | - | - |
| EPS 2 | - | - | - | - | -0.4500 | -0.5300 | -0.2600 | -0.4000 | -0.3800 | -0.3800 | -0.3800 | -0.3900 | -0.4925 | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 30/03/22 | 16/05/22 | 10/08/22 | 10/11/22 | 30/03/23 | 12/05/23 | 14/08/23 | 13/11/23 | 28/03/24 | 13/05/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 519 | 324 | 181 | 208 | 169 | 169 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | -161 | -163 | -164 | -170 |
| ROE (net income / shareholders' equity) | - | -162% | -52.2% | -52.8% | -64.6% | -82.3% | -79.7% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 5.460 | 3.550 | 2.390 | 1.870 | 1.380 | 1.070 |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - |
| Announcement Date | 21/04/21 | 30/03/22 | 30/03/23 | 28/03/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
8.89
USD
Average target price
14.2
USD
Spread / Average Target
+59.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.68% | 1B | |
| +38.36% | 52.5B | |
| +36.73% | 39.31B | |
| -8.63% | 39.01B | |
| +25.46% | 28.2B | |
| -11.17% | 26.57B | |
| +11.44% | 26.2B | |
| +45.09% | 14.15B | |
| +32.93% | 12.62B | |
| -5.30% | 11.74B |
- Stock Market
- Equities
- CNTA Stock
- Financials Centessa Pharmaceuticals plc
